Helicobacter pylori (HP) may cause chronic gastritis, atrophic gastritis, peptic ulcer disease (PUD), even gastric cancer. Eradication therapy can not only heal the injured mucosa, but also prevent PUD relapse and reduce the risk of gastric cancer. National Health Insurance paid for eradication therapy of PUD with HP infection, but not the gastritis patients. So far we don’t have available report regarding health resource utility of such patients who receive eradication therapy. The purpose of this study is to figure out the influence of health resource utility of the HP gastritis patients who receive eradication therapy or not.
This is a retrospective study. We enrolled the patients who receive upper gastrointestinal endoscopy (PES) which showed gastritis and rapid urease testing positive in a district hospital. We collected these patient’s medical data, whether receiving eradication therapy, or the frequency of outpatient access and PES, payments for digestant one year before and after the diagnosis made, then go to the statistic analysis.
After the HP gastritis patients receiving eradication therapy, the frequency of outpatient access and payment of digestant all decreased, while the frequency of PES is the same. If we enroll the fee for eradication therapy, the payment before and after treatment is of no difference. By the way, the patients who did not receive eradication therapy, all items of health resource utility is off no difference before and after follow up.
HP gastritis patients who receiving eradication therapy will reduce the frequency of outpatient access, following decreasing of health resource utility, including fee for registration and co-payments of the patients, and fee for physician visit and drug prescription of National Health Insurance. If the National Health Insurance Administration pay for eradication therapy of HP gastritis patients, it wouldn’t increase the expenditure of the drugs at all.